<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014235</url>
  </required_header>
  <id_info>
    <org_study_id>1596.00</org_study_id>
    <secondary_id>NCI-2012-00671</secondary_id>
    <secondary_id>1596.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00014235</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine and/or Low Dose TBI With Disease-Risk Based Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      This clinical trial studies fludarabine phosphate and total-body radiation followed by donor&#xD;
      peripheral blood stem cell transplant and immunosuppression in treating patients with&#xD;
      hematologic malignancies. Giving chemotherapy and total-body irradiation before a donor&#xD;
      peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop&#xD;
      the patient's immune system from rejecting the donor's stem cells. When the healthy stem&#xD;
      cells from a donor are infused into the patient they may help the patient's bone marrow make&#xD;
      stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted&#xD;
      cells from a donor can make an immune response against the body's normal cells. Giving&#xD;
      total-body irradiation together with fludarabine phosphate, cyclosporine, and mycophenolate&#xD;
      mofetil before transplant may stop this from happening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the rate of grade III/IV graft-versus-host disease (GVHD) in patients treated&#xD;
      with low-dose total body irradiation (TBI), fludarabine (fludarabine phosphate), PBSC&#xD;
      infusion and immunosuppression with mycophenolate mofetil and a disease risk-based&#xD;
      cyclosporine taper.&#xD;
&#xD;
      II. To estimate the risk of graft rejection, GVHD, disease response, non-relapse mortality&#xD;
      and the incidence and severity of infectious complications using this treatment strategy.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
      ARM I (indolent disease):&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -4 to&#xD;
      -2 and undergo TBI on day 0.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo donor peripheral blood stem cell transplantation (PBSCT) on&#xD;
      day 0.&#xD;
&#xD;
      IMMUNOSUPPRESSION: Patients receive cyclosporine orally (PO) twice daily (BID) or IV every&#xD;
      8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV&#xD;
      every 8-12 hours on days 0 to 27.&#xD;
&#xD;
      ARM II (aggressive disease):&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo donor PBSCT on day 0.&#xD;
&#xD;
      IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to&#xD;
      56 with a taper to day 70 and mycophenolate mofetil as in Arm I.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of severe (grade III/IV) GVHD in each arm</measure>
    <time_frame>Up to day 84</time_frame>
    <description>95% confidence interval will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Probability of severe (grade III/IV) GVHD in each arm</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection</measure>
    <time_frame>Day 28</time_frame>
    <description>Chimerism analysis by fluorescent in situ hybridization (FISH) or variable number tandem repeat (VNTR). Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection</measure>
    <time_frame>Day 56</time_frame>
    <description>Chimerism analysis by FISH or VNTR. Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection</measure>
    <time_frame>Day 84</time_frame>
    <description>Chimerism analysis by FISH or VNTR. Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection</measure>
    <time_frame>Day 180</time_frame>
    <description>Chimerism analysis by FISH or VNTR. Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection</measure>
    <time_frame>Day 365</time_frame>
    <description>Chimerism analysis by FISH or VNTR. Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious complications</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of infectious complications</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Examined and reported in a descriptive manner. Confidence intervals will be presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Myeloid Leukemia/Transient Myeloproliferative Disorder</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Mast Cell Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncutaneous Extranodal Lymphoma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Systemic Amyloidosis</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>T-cell Large Granular Lymphocyte Leukemia</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.&#xD;
TRANSPLANTATION: Patients undergo donor PBSCT on day 0.&#xD;
IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.&#xD;
TRANSPLANTATION: Patients undergo donor PBSCT on day 0.&#xD;
IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo PBSCT</description>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo PBSCT</description>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (indolent disease)</arm_group_label>
    <arm_group_label>Arm II (aggressive disease)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or&#xD;
             multiple myeloma who are not eligible for a curative autologous transplantation or who&#xD;
             have received a prior autologous transplantation; patients with NHL or CLL must have&#xD;
             failed prior therapy with an alkylating agent and/or fludarabine, or be at high risk&#xD;
             of relapse; patients with multiple myeloma must have stage II or III disease and&#xD;
             received prior chemotherapy&#xD;
&#xD;
          -  Patients &lt; 50 years of age with NHL, Hodgkin's disease (HD), CLL or multiple myeloma&#xD;
             at high risk of regimen related toxicity through prior autologous transplant or&#xD;
             through pre-existing medical conditions&#xD;
&#xD;
          -  Patients &lt; 75 years of age with other malignant diseases treatable by allogeneic bone&#xD;
             marrow transplant (BMT) whom through pre-existing chronic disease affecting kidneys,&#xD;
             liver, lungs, and heart are considered to be at high risk for regimen related toxicity&#xD;
             using standard high dose regimens; the following diseases are the likely candidates&#xD;
&#xD;
               -  Myelodysplastic syndromes&#xD;
&#xD;
               -  Myeloproliferative syndromes&#xD;
&#xD;
               -  Acute Leukemia with &lt; 10% blasts&#xD;
&#xD;
               -  Amyloidosis&#xD;
&#xD;
               -  Hodgkin's disease&#xD;
&#xD;
          -  The Fred Hutchinson Cancer Research Center (FHCRC) Patient Care Conference (PCC) may&#xD;
             approve patients with other malignancies or patients declining standard allografts for&#xD;
             transplant following presentation and approval; centers outside the FHCRC that have a&#xD;
             PCC or equivalent should obtain their Institutional approval; if there is not a&#xD;
             comparable group at the Institution, please contact the FHCRC Principal Investigator&#xD;
             for FHCRC approval through PCC&#xD;
&#xD;
          -  DONOR: Human leukocyte antigen (HLA) genotypically or phenotypically identical related&#xD;
             donor&#xD;
&#xD;
          -  DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis&#xD;
&#xD;
          -  DONOR: Donor must have adequate veins for leukapheresis or agree to placement of&#xD;
             central venous catheter (femoral, subclavian)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible for a high-priority curative autologous transplant&#xD;
&#xD;
          -  Patients with rapidly progressive aggressive NHL unless in minimal disease state&#xD;
&#xD;
          -  Any current central nervous system (CNS) involvement with disease&#xD;
&#xD;
          -  Fertile men or women unwilling to use contraceptive techniques during and for 12&#xD;
             months following treatment&#xD;
&#xD;
          -  Females who are pregnant&#xD;
&#xD;
          -  Patients who are human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 40%; ejection fraction is required if the patient has a&#xD;
             history of anthracyclines or history of cardiac disease&#xD;
&#xD;
          -  Receiving supplementary continuous oxygen&#xD;
&#xD;
          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &lt; 30%&#xD;
&#xD;
          -  Total lung capacity (TLC) &lt; 30%&#xD;
&#xD;
          -  Forced expiratory volume in one second (FEV1) &lt; 30%&#xD;
&#xD;
          -  Total bilirubin &gt; 2x the upper limit of normal&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic&#xD;
             transaminase (SGOT) 4x the upper limit of normal&#xD;
&#xD;
          -  Karnofsky score &lt; 50&#xD;
&#xD;
          -  Patients with poorly controlled hypertension who are unable to have blood pressure&#xD;
             kept below 150/90 on standard medication&#xD;
&#xD;
          -  Patients with renal failure are eligible, however patients with renal compromise&#xD;
             (serum creatinine greater than 2.0) will likely have further compromise in renal&#xD;
             function and may require hemodialysis (which may be permanent) due to the need to&#xD;
             maintain adequate serum cyclosporine levels&#xD;
&#xD;
          -  The addition of cytotoxic agents for &quot;cytoreduction&quot; with the exception of hydroxyurea&#xD;
             and imatinib mesylate will not be allowed within two weeks of the initiation of&#xD;
             conditioning&#xD;
&#xD;
          -  DONOR: Identical twin&#xD;
&#xD;
          -  DONOR: Age less than 12 years&#xD;
&#xD;
          -  DONOR: Pregnancy&#xD;
&#xD;
          -  DONOR: Infection with HIV&#xD;
&#xD;
          -  DONOR: Inability to achieve adequate venous access&#xD;
&#xD;
          -  DONOR: Known allergy to G-CSF&#xD;
&#xD;
          -  DONOR: Current serious systemic illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Maloney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Leukemia, Mast-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

